The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.
 
Jiani Wang
No Relationships to Disclose
 
Qing Li
No Relationships to Disclose
 
Yuxin Mu
No Relationships to Disclose
 
Tongtong Zhang
No Relationships to Disclose
 
Ying Han
No Relationships to Disclose
 
Jiayu Wang
No Relationships to Disclose
 
Qiao Li
No Relationships to Disclose
 
Yang Luo
No Relationships to Disclose
 
Peng Yuan
No Relationships to Disclose
 
Fei Ma
No Relationships to Disclose
 
Ying Fan
No Relationships to Disclose
 
Pin Zhang
No Relationships to Disclose
 
Binghe Xu
No Relationships to Disclose